Brief: Humacyte Q2 Operating Expenses USD 29.499 Million
13/08/2024 12:00
Aug 13 (Reuters) - Humacyte Q2 operating income USD -29.499 million vs. IBES estimate USD -27.8 million. * Q2 basic EPS USD -0.48 * Q2 net income USD -56.663 million vs. IBES estimate USD -27.3 million
Recent news on Humacyte
See all newsBrief: Humacyte Announces Lancet Digital Health Publication Of V007 Phase 3 Hemodialysis Access Trial Results
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Humacyte falls after wider-than-expected quarterly loss
Humacyte Inc reports results for the quarter ended June 30 - Earnings Summary